CGTX - Cognition Therapeutics to Present at the TD Cowen Health Care Conference | Benzinga
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition's pipeline progress, including upcoming clinical milestones and recent corporate achievements.
Details of Cognition's presentation are as follows:
Event: TD Cowen Health Care Conference
Date/Time: Monday, March 4, 2024 at 2:50 p.m. Eastern Time
Webcast: https://wsw.com/webcast/cowen154/cgtx/2028516
A live webcast of the presentation will be available on the "events and presentations" section of Cognition's investor relations site, and an archived replay will be available for playback 90 days following the event.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of ?-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the ?-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements ...